Search

An interview with physician Mark D. Tyson is presented. Tyson discusses the current standard of care for both Bacille Calmette-Guerin (BCG)-naive non-muscle invasive bladder cancer (NMIBC) and BCG-unresponsive high-risk NMIBC, the technology and delivery system behind TAR-200 device, and the SunRise3 study comparing TAR-200 monotherapy induction and maintenance versus TAR-200 plus cetrelimab induction and maintenance versus BCG, and the potential effect of TAR-200 on NMIBC treatment.

This section offers news briefs on drug approvals by the U.S. Food and Drug Administration in urology as of December 2023. The LithoVue Elite Single-Use Digital Flexible Ureteroscope System was given 510(k) clearance. A supplemental drug application for Illuccix, a radiopharmaceutical cold kit for the preparation of gallium-68 gozetotide injection, was approved for metastatic prostate cancer treatment. The enfortumab vedotin/pembrolizumab combination was approved for urothelial cancer.

An interview with Edward M. Messing MD on the apalutamide trial and study on non-muscle invasive bladder cancer in 2024 is presented. When asked on the study's background, he replies that the androgen receptor helps in bladder cancer development, and that the antiandrogen apalutamide has potential to fight the androgen receptor. Messing states that apalutamide will likely reduce the recurrence of this common disease. He notes that the treatment makes castrative therapies more effective.

A recent study from the Department of Urology in Winston-Salem, North Carolina, compared the efficacy and tolerance of sequential intravesical chemotherapy (Gemcitabine-Docetaxel) to bacillus Calmette-Guerin (BCG) in patients with high-risk non-muscle invasive bladder cancer. The study found that Gem-Doce showed similar oncologic outcomes to BCG with fewer adverse events, making it a potentially better-tolerated alternative for treatment-naive patients. The research, published in Urology, suggests that Gem-Doce could be a viable option for HR-NMIBC patients. [Extracted from the article]

The article discusses a Phase 1/2 clinical study evaluating the safety and efficacy of Sacituzumab Tirumotecan in participants with intermediate-risk nonmuscle invasive bladder cancer. The study aims to determine the highest tolerable dose of the drug when administered intravesically and assess its effectiveness for future studies. The trial is not yet recruiting participants, with a completion date set for November 30, 2026. Key inclusion criteria include a history of low-grade nonmuscle invasive bladder cancer and visible tumors by cystoscopy, while exclusion criteria involve certain medical conditions and recent vaccinations. [Extracted from the article]

A patent has been issued for peptides, a combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers. Bladder cancer is described in detail, including its types, stages, treatment options, and survival rates. The patent focuses on a peptide sequence and its variants that bind to MHC and induce T cells, potentially offering new avenues for immunotherapy in bladder cancer treatment. [Extracted from the article]

Researchers at the Carolina Urologic Research Center in Myrtle Beach, South Carolina, have conducted a study on the clinical use of nadofaragene firadenovec-vncg for high-risk non-muscle-invasive bladder cancer (NMIBC) patients who are unresponsive to standard treatment. This gene therapy, which delivers copies of the gene encoding for interferon alpha-2b to urothelial cells, has shown promising results in a phase III study, with over half of participants exhibiting a complete response by month 3. The study highlights the potential of nadofaragene firadenovec-vncg as a bladder-preserving option for patients with BCG-unresponsive NMIBC, offering a unique treatment approach with favorable efficacy and safety profiles. [Extracted from the article]

Researchers at the University of Foggia have conducted a study on bladder cancer imaging techniques, including conventional methods like ultrasonography and computed tomography, as well as newer technologies like contrast-enhanced ultrasonography and dual-energy computed tomography. The study emphasizes the critical role of imaging in detecting and staging bladder cancer, with a focus on differentiating muscle-invasive from non-muscle-invasive cancer. Integrated imaging modalities, such as positron emission tomography combined with computed tomography or magnetic resonance imaging, show promise for bladder cancer staging. For more information, the full article is available in Digital Diagnostics, published by Eco-Vector. [Extracted from the article]

A recent study conducted by the Department of Urology at Mersin University aimed to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting recurrence and treatment response in patients with non-muscle invasive bladder cancer (NMIBC) undergoing intravesical BCG therapy. The study found that patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence, suggesting a potential role for fibronectin as a prognostic biomarker. However, the predictive value of serum fibronectin levels for BCG treatment response remains limited. This research provides valuable insights into novel biomarkers and treatment strategies for bladder cancer. [Extracted from the article]

A new study conducted at Stavanger University Hospital in Norway explores the use of genetic alterations and histopathological features as prognostic biomarkers for non-muscle-invasive bladder cancer (NMIBC). The study found that certain genetic alterations, such as FGFR3 and PIK3CA, were more prevalent in Ta tumors, while ERBB2 alterations were more common in T1 tumors. Additionally, the study found that the mitotic activity index (MAI) was the strongest predictor for progression-free survival (PFS). The researchers suggest that integrating genetic alterations and histopathological features could improve risk stratification in NMIBC. [Extracted from the article]

A patent application titled "Methods Of Treating Cancers Using Pd-1 Axis Binding Antagonists And Taxanes" has been published online. The application discusses the use of PD-1 axis binding antagonists and taxanes in the treatment of various cancers. The invention aims to enhance immune function and delay the progression of cancer by administering these agents. The patent application provides detailed information on the specific types of cancers that can be treated and the potential therapeutic benefits of this approach. The patent application describes methods for treating or delaying the progression of various types of cancer by administering a combination of a human PD-1 axis binding antagonist and a taxane. The cancers that can be treated include lung cancer, bladder cancer, breast cancer, renal cell carcinoma, melanoma, colorectal cancer, and heme malignancies. The methods aim to enhance immune function and can be used in individuals who have been diagnosed with cancer and whose cancer cells express PD-L1. The patent application also includes additional claims and can be accessed for further information. [Extracted from the article]

Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer that remains confined to the innermost lining layer of the bladder without spreading into the muscle. It is a common form of bladder cancer and is usually associated with superficial tumor growth. The current treatment plan for NMIBC involves surgery, intravesical immunotherapy, and intravesical chemotherapy. The FDA has approved three drugs for treating NMIBC: KEYTRUDA, ADSTILADRIN, and ANKTIVA. There are also several other potential therapies in development for NMIBC. The market size for NMIBC is expected to grow significantly in the coming years. [Extracted from the article]

A study conducted at West Virginia University examined the efficacy of a novel platinum analog called Dicycloplatin (DCP) in inhibiting the growth of urothelial carcinoma (UC) cells. Platinum-based chemotherapies are commonly used in the treatment of UC, but they can have dose-limiting side effects. The study found that DCP demonstrated cell-killing efficacy in a time- and concentration-dependent manner in grade II-IV UC cell lines, suggesting its potential use in the treatment of bladder UC. Further research is needed to explore the use of DCP in different treatment settings. [Extracted from the article]

A patent has been issued to Cg Oncology Inc. for methods of treating solid or lymphatic tumors using combination therapy. The patent describes a method that involves locally administering an oncolytic virus to the tumor site and systemically administering an immunomodulator. The oncolytic virus is designed to replicate in cancer cells and contains a gene encoding an immune-related molecule. The immunomodulator helps activate the immune system to fight against the tumor. This method aims to improve the efficacy of cancer immunotherapy, which has faced challenges in the past. [Extracted from the article]

A study conducted by researchers at the Fourth Military Medical University in China explores the use of liposomes to enhance the effectiveness of cancer gene therapy. The researchers prepared liposomes loaded with the drugs chlorin e6 (Ce6) and elemene (ELE), which have anti-tumor properties. The liposomes showed suitable properties for drug delivery and effectively inhibited tumor growth and induced apoptosis in vitro. In vivo experiments also demonstrated significant anti-tumor effects. The study suggests that these liposomes can enhance apoptosis in non-muscle invasive bladder cancer (NMIBC) through light-controlled release and reactive oxygen species (ROS) response. [Extracted from the article]

A recent report from Ankara, Turkey discusses research findings on bladder cancer. The study focused on the impact of glutathione, an antioxidant defense mechanism, on the development and prognosis of non-muscle-invasive bladder cancer. The study included 98 patients with bladder cancer and 30 healthy controls. The results showed that glutathione levels differed among the patient groups, but did not significantly affect the prognosis of bladder cancer. The researchers recommend further studies with larger patient cohorts to fully understand the impact of glutathione on bladder cancer prognosis. [Extracted from the article]

A patent application titled "Urinary Tract Cancer Treatment Guided By Mutational Landscape" has been published online. The application provides information on the prevalence and mortality rates of urinary tract cancers, with a focus on bladder cancer, in the United States. It discusses the genetic and environmental factors that contribute to the development and progression of bladder cancer, as well as the challenges in predicting chemotherapy responsiveness. The inventors propose using the inactivation of the CDKN1A gene as a biomarker for predicting chemotherapy responsiveness and suggest further research to improve precision therapies for bladder cancer. The application also highlights the association between environmental agents and an increased risk of bladder cancer. The patent application presents a method for treating urinary tract cancer, specifically bladder cancer, based on the mutational landscape of the tumor. The method involves identifying loss-of-function mutations in specific genes (CDKN1A and RB1) and selecting treatment options accordingly, which may include a combination of a checkpoint kinase inhibitor and a DNA damaging agent. The invention aims to provide targeted therapies for bladder cancer patients with specific genetic mutations. [Extracted from the article]

Bladder cancer is the fifth most common cancer in Canada and affects more men than women. In 2024, it is estimated that 12,300 Canadians will be diagnosed with bladder cancer, with about 2,300 expected to die from the disease. Symptoms of bladder cancer include blood in the urine, bladder spasms, increased frequency and urgency of urination, and pain in the back, pelvic, or groin area. Treatment options for bladder cancer include surgery, radiation, chemotherapy, and immunotherapy. New treatment options are being developed to improve the quality of life and survival rates for patients with advanced bladder cancer. [Extracted from the article]

New data from the TAR-200 Phase 2b SunRISe-1 study conducted by Johnson & Johnson shows that the investigational TAR-200 treatment has an 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) immunotherapy. The results were presented at the European Society of Medical Oncology (ESMO) 2024 Congress. The study's findings suggest that TAR-200 could be a promising targeted releasing system for patients who do not respond to BCG immunotherapy and are faced with radical cystectomy as a treatment option. [Extracted from the article]

This document is a patent application for a chemically modified small activating RNA (saRNA) that aims to improve the pharmaceutical properties of saRNA oligonucleotides. The modifications to the nucleotide strands in the saRNA include sulfur and borane modifications, phosphorothioate modifications, and chemical modifications of the ribose 2'-OH. The saRNA can be used to target specific genes, such as the human p21WAF1/CIP1 gene, and has potential applications in cancer gene therapy. The patent application provides detailed information on the specific modifications and patterns used in the saRNA. [Extracted from the article]

Immatics Biotechnologies GmbH has been granted a patent for peptides and cell-based medicaments that can be used in immunotherapy for urinary bladder cancer and other cancers. The patent explains the different types and stages of bladder cancer, as well as the standard treatments available. The invention focuses on a peptide sequence that can bind to MHC and stimulate T cells that react with the peptide, potentially aiding in the diagnosis and treatment of bladder cancer. The patent also mentions the use of adjuvants and pegylation in the composition of the peptides. This article provides a summary of various topics related to surgery, genetics, oncology, and bladder cancer, presenting research on cystectomy, immunology, lymph nodes, chemotherapy, bone research, immunotherapy, urinary diversion, papillary cancer, drugs and therapies, post-trial research, and risk and prevention. It is a fact-based report that aims to deliver news on research and discoveries from around the world. [Extracted from the article]

A recent study conducted by researchers at the University of Leeds in the United Kingdom explores alternative treatments for high-risk non-muscle invasive bladder cancer. The current treatment of choice, radical cystectomy, negatively impacts quality of life, leading clinicians to investigate other options. The study, called INVEST, aims to investigate the safety and effectiveness of intravesical atezolizumab, a PDL1 inhibitor, administered either through passive instillation or direct injection into the bladder wall. The study will assess the pharmacokinetic profile of atezolizumab, as well as its effects on tumor cells and immune cell composition. [Extracted from the article]

Researchers at Shiraz University of Medical Sciences conducted a systematic review and meta-analysis to determine the prognostic value of the systemic immune-inflammation index (SII) and related markers in bladder cancer patients receiving Bacillus Calmette-Guerin (BCG) immunotherapy. The study found that elevated pre-treatment SII was associated with worse progression-free survival and recurrence-free survival. Additionally, other inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) showed potential prognostic value. The researchers concluded that SII and other inflammatory markers may predict poor outcomes after BCG immunotherapy and further studies are needed to validate these findings. [Extracted from the article]

A recent study conducted by researchers at Yonsei University College of Medicine in Seoul, South Korea, examined the short-term outcomes of using intravesical gemcitabine as a treatment for non-muscle-invasive bladder cancer (NMIBC). The study included 60 patients with high- or very high-risk NMIBC who received weekly intravesical gemcitabine for 6 weeks after transurethral resection of bladder tumor (TURBT). The study found that there was a similar disease-free survival (DFS) outcome between high-risk and very high-risk patients in the short-term. However, the researchers noted that further studies with more patients and long-term outcomes are needed to confirm these findings. [Extracted from the article]

A recent report from the Department of Anesthesiology and Intensive Care in Sofia, Bulgaria, highlights the role of spinal anesthesia in improving postoperative oncologic outcomes for non-muscle invasive bladder cancer patients undergoing transurethral resection of the bladder tumor (TURBT). The study found that spinal anesthesia compared to general anesthesia improved outcomes, and the coadministration of opioids did not affect NK cells function and improved postoperative opioid sparing. The research suggests that spinal anesthesia with intrathecal opioid coadministration may play a significant complementary role in improving oncologic outcomes after TURBT for bladder cancer. [Extracted from the article]

A. Menarini Diagnostics and Nucleix have formed a partnership to distribute the Bladder EpiCheck test in Europe. This non-invasive urine test is used to detect primary or recurrent bladder cancer and upper tract urinary cancer. It is recommended by the European Association of Urology as a tool for initial diagnosis and follow-up monitoring. The test has the potential to reduce the need for invasive cystoscopies and improve patient outcomes. The partnership aims to expand the availability of the test and improve bladder cancer care in Europe. [Extracted from the article]

This article describes two case reports of patients who developed reactive arthritis during treatment for non-muscle-invasive bladder cancer. The first patient, a 68-year-old man, experienced joint pain and swelling after receiving intravesical BCG immunotherapy. He was diagnosed with BCG-induced reactive arthritis and was treated with NSAIDs and prednisolone, which improved his symptoms. The second patient, a 69-year-old man, also developed reactive arthritis after receiving BCG treatment. He was initially treated with NSAIDs and prednisolone, but experienced adverse reactions to sulfasalazine and methotrexate. Both patients had negative results for tumor recurrence during follow-up. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the resistance to Mycobacterium bovis Bacillus Calmette-Guerin (BCG) immunotherapy in non-muscle-invasive bladder cancer (NMIBC). The study found that prolonged exposure to interferon (IFN)-gamma, a cytokine stimulated by BCG, can lead to adaptive resistance in recurrent tumors, promoting immune evasion and tumor growth. The researchers identified HLA-E and NKG2A as key mediators of resistance in BCG-unresponsive NMIBC. They suggest that a combined NKG2A and PD-L1 blockade strategy could be used for bladder-sparing treatment of BCG-unresponsive NMIBC. It is important to note that this preprint has not been peer-reviewed. [Extracted from the article]

The article presents the discussion on current state of therapies for high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer, noting the limitations of existing treatments and the promise of new gene therapies. Topics include advancements in drug delivery systems, recent FDA-approved biologics; and ongoing clinical trials for second-line therapies.

The article presents the discussion on alternative treatments for non-muscle invasive bladder cancer resistant to Bacillus Calmette-Guerin (BCG) therapy, highlighting the need for new options due to BCG's limitations and resistance issues. Topics include the exploration of intravesical chemotherapy, immunotherapy, and gene therapy as alternatives, the impact of BCG resistance on treatment strategies; and the necessity of addressing the global BCG shortage with innovative approaches.

A recent study from the University of Iowa Hospitals provides new insights into the mechanism of action of intravesical Bacillus Calmette-Guerin (BCG) therapy for non-muscle-invasive bladder cancer (NMIBC). While the precise mechanism of BCG's anti-tumor action is not fully understood, three new concepts have emerged. First, BCG interacts with cancer cells, inducing them to act as antigen-presenting cells for T-cells. Second, BCG has a direct cytotoxic effect on cancer cells. Third, BCG can increase the expression of programmed death ligand 1 (PD-L1) to impair the immune response. This improved understanding may lead to new strategies for enhancing the efficacy of BCG therapy. [Extracted from the article]

This document provides information about two clinical trials related to cancer research. The first trial, NCT06565923, focuses on the use of artificial intelligence and multimodal omics features in the staging and prognosis monitoring of bladder cancer. The trial involves gathering patient information from 2012 to 2023, including MRI images, blood/urine samples, and tissue samples. Deep learning and machine learning models will be used to analyze the data. The second study mentioned in the document is a retrospective study on using deep learning to distinguish pancreatic cancer tissue from non-cancerous tissue. The document also includes recruitment information for a separate study on bladder cancer. Specific findings or results from the studies are not provided. [Extracted from the article]

A recent study conducted by researchers at the National University of Singapore has found that the presence of the Glutathione-S-transferase Theta 2 (GSTT2) enzyme in bladder cancer patients affects their response to Bacillus Calmette-Guerin (BCG) immunotherapy. The study analyzed the association between GSTT1, GSTT2, and GSTT2B enzymes and the response to BCG therapy in non-muscle-invasive bladder cancer treatment. The results showed that patients with GSTT2BDel/Del genotype responded better to less BCG therapy and may be candidates for a reduced surveillance regimen. This research provides valuable insights into personalized treatment options for bladder cancer patients. [Extracted from the article]

A recent study conducted by researchers at Chongqing University compared the outcomes of two surgical procedures, pelvic organ-preserving radical cystectomy (POPRC) and standard radical cystectomy (SRC), in female patients diagnosed with bladder cancer. The study found that while POPRC resulted in a better postoperative quality of life, it raised concerns about its oncological outcomes. The researchers analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database and found that after propensity score matching, POPRC was associated with significantly worse overall survival compared to SRC. The study suggests that stricter criteria should be implemented for selecting candidates for POPRC to achieve satisfactory oncological outcomes. However, the researchers acknowledge that more evidence is needed to support their findings. [Extracted from the article]

Bladder cancer is a challenging and costly cancer to treat, and there has been little progress in developing predictive biomarkers and targeted therapies. However, a recent study has identified the loss of the tumor suppressor protein Numb as a causal alteration in bladder cancer that drives aggressiveness and disease progression. The study found that Numb-deficient tumors are associated with worse overall survival in muscle-invasive bladder cancer patients and increased risk of progression in non-muscle-invasive bladder cancer patients. The loss of Numb leads to heightened proliferative and invasive potential in bladder cancer cells, and this is mediated by the activation of the RhoA/ROCK/YAP signaling pathway. The findings suggest that targeting this pathway could be a potential therapeutic strategy for aggressive bladder cancer. [Extracted from the article]

The article focuses on a clinical trial, NCT06574568, which aims to advance the development of the drug YKST02 for treating multiple myeloma. It explains the trial's design, including primary outcomes like dose-limiting toxicities, adverse events, and overall response rate, along with secondary measures such as pharmacokinetics and antibody responses.

A patent has been issued for methods of treating tumor metastasis. The patent describes a method of locally delivering a chemotherapeutic agent, such as gemcitabine, to the bladder for a prolonged period of time to treat or suppress tumor metastasis at a site distinct from the bladder. The method has shown an extraordinary antitumor effect and can be used to treat non-bladder tumors as well. The patent also includes definitions and claims related to inducing an immune response against tumor cells. [Extracted from the article]

The article discusses highlights of the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium held in San Francisco, California. Topics included link of darolutamide to fewer hospitalizations in metastatic hormone-sensitive prostate cancer patients, cabozantinib and pembrolizumab therapy for urothelial carcinoma, and urinary minimal residual disease-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in non-muscle-invasive bladder cancer.

The article highlights advancements in the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). These include nadofaragene firadenovec intravesical gene therapy, pembrolizumab systemic therapy, TAR-200 drug intravesical delivery system using gemcitabine and gemcitabine plus a PD-L1 inhibitor, combination chemotherapy with gemcitabine and docetaxel, and QUILT-3.032 study on the synergy between immune checkpoint inhibitors and targeted therapies.

An interview with Doctors Ashish M. Kamat, Roger Li, and Wei Shen Tan about the role of guidelines in the management of non-muscle-invasive bladder cancer (NMIBC), is presented. They discuss the updated consensus definition and management recommendations from the International Bladder Cancer Group (IBCG), how the guidelines differ when it comes to intermediate-risk NMIBC, and how these guidelines can be refined and simplified for the clinician in a user-friendly fashion.

A recent study conducted at the University of Iowa Hospitals and Clinic investigated the role of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in predicting the response to sequential intravesical therapy for high-risk non-muscle-invasive bladder cancer (NMIBC). The study analyzed data from 115 patients who received gemcitabine and docetaxel therapy for NMIBC. The results showed that NLR was associated with recurrence-free survival (RFS), indicating its potential as a predictive marker for RFS in high-risk BCG-naive patients. However, further prospective trials are needed to validate these findings. [Extracted from the article]

A recent study conducted at the University of Texas MD Anderson Cancer Center has highlighted the advances in cancer gene therapy, specifically focusing on the evolution of nadofaragene firadenovec as a treatment for non-muscle invasive bladder cancer (NMIBC). Nadofaragene firadenovec is a non-replicating recombinant adenovirus vector that delivers the human interferon alpha-2b gene into urothelial and tumor cells, resulting in the expression of this cytokine with potent antitumor effects. The therapy has been FDA approved and represents a significant milestone in urologic oncology. Ongoing research aims to improve patient selection and enhance therapeutic response through the study of resistance mechanisms and prognostic biomarkers. [Extracted from the article]

The article discusses a new clinical trial focusing on the immunohistochemical expression of ALDOA in bladder urothelial carcinoma and its correlation with clinical factors and prognosis. Topics include the evaluation of ALDOA expression in bladder cancer specimens, its relationship with clinicopathological features, and its impact on patient survival and prognosis.

A recent study conducted by researchers at the University of Sao Paulo in Brazil focused on bladder cancer, which is the second most common type of cancer in the urinary system. The study aimed to explore the use of urinary mRNA-based biomarkers as an alternative to current diagnostic and surveillance methods for non-muscle-invasive bladder cancer (NMIBC). The researchers found 11 original studies that utilized mRNA-based urinary biomarkers, but noted that these studies did not exclusively focus on NMIBC. They concluded that further randomized interventional trials are needed to develop effective follow-up biomarkers for NMIBC. [Extracted from the article]

The article offers information on a study from Roswell Park Comprehensive Cancer Center, New York, evaluating the effects of a dietary intervention on bladder cancer outcomes. Topics discussed include the increased Cruciferae intake and urinary isothiocyanates (ITCs) levels in patients; the efficacy of the intervention compared to a control group and the potential for this approach to be a cost-effective strategy for improving prognosis in non- muscle -invasive bladder cancer (NMIBC) survivors.

Photocure ASA, a company specializing in bladder cancer treatment, reported revenues of NOK 122.4 million in the second quarter of 2024, with a growth of 6% compared to the previous year. The company also reported positive EBITDA of NOK 27.8 million. Photocure expects new installations of its Saphira system in the U.S. to range from 55 to 70 towers for the full year. The company also announced a partnership with Richard Wolf to develop and commercialize a high-definition flexible blue light system for bladder cancer detection. Photocure believes that its technology will become the standard of care for bladder cancer management. [Extracted from the article]

The global non-muscle invasive bladder cancer market is projected to experience significant growth, with a projected compound annual growth rate (CAGR) of 21% over the next decade. By 2034, the market is expected to reach a value of US$ 21.1 billion, compared to its value of US$ 2.6 billion in 2023. Bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC), is more common in men and the elderly. The increasing incidence of NMIBC worldwide is driving the growth of the market. Governments are investing in intravesical anti-cancer therapies and maintenance therapy to reduce the risk of recurrence, leading to an expansion of the market. Chemotherapy is expected to remain a prominent treatment option, and hospital pharmacies are the primary sales points for non-invasive muscle bladder cancer treatment drugs. [Extracted from the article]

A study conducted in Olsztyn, Poland, explored the potential role of Semaphorin 6D (Sema6D) in bladder cancer. The study found that there was a significantly higher concentration of urinary Sema6D in patients with non-muscle-invasive bladder cancer (NMIBC) compared to controls. However, there was no significant difference in plasma Sema6D levels. The researchers concluded that urinary Sema6D could potentially be used as a marker for diagnosing NMIBC and monitoring treatment efficacy, but it is not associated with the grading or staging of the disease. [Extracted from the article]

A patent has been issued for a device designed to reduce the risk of complications during electrosurgical interventions. The device is particularly useful for procedures such as transurethral electro-resection of the bladder, transurethral electro-resection of the prostate, and transcervical resection. It includes a generator for creating treatment voltage, an instrument with electrodes, and a sensor attached to the patient to detect movement. The device's control device can quickly recognize muscle contractions caused by neuromuscular stimulation and adjust the generator's operation to prevent undesired patient movements and potential complications. [Extracted from the article]

A study conducted at the Jawaharlal Institute of Postgraduate Medical Education and Research in Puducherry, India, explored treatment adherence patterns in patients with nonmuscle invasive bladder cancer (NMIBC). The study found that a significant number of patients were nonadherent to follow-up protocols, with inadequate physician explanation being the primary cause of nonadherence. Other factors that impacted adherence included economic constraints and side effects of treatment. The study highlights the need for tailored interventions to improve patient education, communication, and economic support in order to enhance adherence to NMIBC follow-up protocols. [Extracted from the article]